{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T07:09:29Z","timestamp":1781680169153,"version":"3.54.5"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100015199","name":"Halozyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015199","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncol Ther"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s40487-025-00360-4","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T08:51:55Z","timestamp":1752655915000},"page":"695-710","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-World Quantitative Insights into the Treatment Experience of Patients with Cancer in the USA with Subcutaneous Versus Intravenous Drug Delivery"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5031-302X","authenticated-orcid":false,"given":"Robert","family":"Epstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9627-6727","authenticated-orcid":false,"given":"JoAnn","family":"Krenitsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0893-9348","authenticated-orcid":false,"given":"Phillip","family":"Sarocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,16]]},"reference":[{"issue":"1","key":"360_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s40259-023-00626-1","volume":"38","author":"B Bittner","year":"2024","unstructured":"Bittner B, Schmidt J. Advancing subcutaneous dosing regimens for biotherapeutics: clinical strategies for expedited market access. BioDrugs. 2024;38(1):23\u201346.","journal-title":"BioDrugs"},{"issue":"1","key":"360_CR2","doi-asserted-by":"publisher","first-page":"2402713","DOI":"10.1080\/19420862.2024.2402713","volume":"16","author":"P Green","year":"2024","unstructured":"Green P, Schneider A, Lange J. Navigating large-volume subcutaneous injections of biopharmaceuticals: a systematic review of clinical pipelines and approved products. MAbs. 2024;16(1):2402713.","journal-title":"MAbs"},{"key":"360_CR3","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.addr.2020.05.009","volume":"167","author":"M Sanchez-Felix","year":"2020","unstructured":"Sanchez-Felix M, Burke M, Chen HH, Patterson C, Mittal S. Predicting bioavailability of monoclonal antibodies after subcutaneous administration: open innovation challenge. Adv Drug Deliv Rev. 2020;167:66\u201377.","journal-title":"Adv Drug Deliv Rev"},{"issue":"28","key":"360_CR4","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.2217\/fon-2019-0368","volume":"15","author":"KC Anderson","year":"2019","unstructured":"Anderson KC, Landgren O, Arend RC, Chou J, Jacobs IA. Humanistic and economic impact of subcutaneous versus intravenous administration of oncology biologics. Future Oncol. 2019;15(28):3267\u201381.","journal-title":"Future Oncol"},{"key":"360_CR5","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.jconrel.2020.02.036","volume":"321","author":"DS Collins","year":"2020","unstructured":"Collins DS, Sanchez-Felix M, Badkar AV, Mrsny R. Accelerating the development of novel technologies and tools for the subcutaneous delivery of biotherapeutics. J Control Release. 2020;321:475\u201382.","journal-title":"J Control Release"},{"key":"360_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2024.115322","volume":"209","author":"J Stevenson","year":"2024","unstructured":"Stevenson J, Poker R, Schoss J, Campbell M, Everitt C, Holly B, et al. Pharmaceutical and biotech industry perspectives on optimizing patient experience and treatment adherence through subcutaneous drug delivery design. Adv Drug Deliv Rev. 2024;209: 115322.","journal-title":"Adv Drug Deliv Rev"},{"issue":"8","key":"360_CR7","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1200\/JCO.21.02504","volume":"40","author":"HE Dzimitrowicz","year":"2022","unstructured":"Dzimitrowicz HE, Armstrong AJ. Elevating the patient voice in metastatic hormone-sensitive prostate cancer clinical trials. J Clin Oncol. 2022;40(8):807\u201310.","journal-title":"J Clin Oncol"},{"key":"360_CR8","first-page":"1","volume":"42","author":"JH Benbow","year":"2022","unstructured":"Benbow JH, Rivera DR, Lund JL, Feldman JE, Kim ES. Increasing inclusiveness of patient-centric clinical evidence generation in oncology: real-world data and clinical trials. Am Soc Clin Oncol Educ Book. 2022;42:1\u201311.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"360_CR9","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.ejca.2021.03.047","volume":"152","author":"J O\u2019Shaughnessy","year":"2021","unstructured":"O\u2019Shaughnessy J, Sousa S, Cruz J, Fallowfield L, Auvinen P, Pulido C, et al. Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): a randomised, open-label phase II study. Eur J Cancer. 2021;152:223\u201332.","journal-title":"Eur J Cancer"},{"issue":"10","key":"360_CR10","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1093\/annonc\/mdu364","volume":"25","author":"X Pivot","year":"2014","unstructured":"Pivot X, Gligorov J, Muller V, Curigliano G, Knoop A, Verma S, et al. Patients\u2019 preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study. Ann Oncol. 2014;25(10):1979\u201387.","journal-title":"Ann Oncol"},{"issue":"9","key":"360_CR11","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2023-0171","volume":"13","author":"V Bril","year":"2024","unstructured":"Bril V, Lampe J, Cooper N, Kiessling P, Gardulf A. Patient-reported preferences for subcutaneous or intravenous administration of parenteral drug treatments in adults with immune disorders: a systematic review and meta-analysis. J Comp Eff Res. 2024;13(9): e230171.","journal-title":"J Comp Eff Res"},{"issue":"9","key":"360_CR12","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1177\/1060028013503122","volume":"47","author":"MS Barbee","year":"2013","unstructured":"Barbee MS, Harvey RD, Lonial S, Kaufman JL, Wilson NM, McKibbin T, et al. Subcutaneous versus intravenous bortezomib: efficiency practice variables and patient preferences. Ann Pharmacother. 2013;47(9):1136\u201342.","journal-title":"Ann Pharmacother"},{"issue":"9","key":"360_CR13","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1080\/14737167.2023.2249232","volume":"23","author":"A Parra","year":"2023","unstructured":"Parra A, Hernandez C, Prieto-Pinto L. Evaluation of the economic benefits, administration times, and patient preferences associated with the use of biotechnological drugs administered subcutaneously and intravenously in patients with cancer: a systematic review. Expert Rev Pharmacoecon Outcomes Res. 2023;23(9):1017\u201326.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"4","key":"360_CR14","doi-asserted-by":"publisher","first-page":"e542","DOI":"10.1200\/OP.22.00421","volume":"19","author":"SA Soefje","year":"2023","unstructured":"Soefje SA, Carpenter C, Carlson K, Awasthi S, Lin TS, Kaila S, et al. Clinical administration characteristics of subcutaneous and intravenous administration of daratumumab in patients with multiple myeloma at Mayo Clinic infusion centers. JCO Oncol Pract. 2023;19(4):e542\u20139.","journal-title":"JCO Oncol Pract"},{"issue":"3","key":"360_CR15","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1200\/OP.24.00021","volume":"21","author":"AG Waks","year":"2025","unstructured":"Waks AG, Chen EL, Graham N, Frey AM, Almeida K, Attaya V, et al. Subcutaneous vs intravenous trastuzumab\/pertuzumab: a time and motion substudy of a Phase II trial of adjuvant trastuzumab\/pertuzumab for Stage I HER2+ breast cancer (ADEPT trial). JCO Oncol Pract. 2025;21(3):351\u20137.","journal-title":"JCO Oncol Pract."},{"key":"360_CR16","doi-asserted-by":"publisher","first-page":"695","DOI":"10.2147\/CEOR.S212257","volume":"11","author":"O Delgado S\u00e1nchez","year":"2019","unstructured":"Delgado S\u00e1nchez O, Guti\u00e9rrez A, do Pazo F, Gin\u00e9s J, Martorell C, Boyeras B, et al. Comparative cost analysis of intravenous and subcutaneous administration of rituximab in lymphoma patients. Clinicoecon Outcomes Res. 2019;11:695\u2013701.","journal-title":"Clinicoecon Outcomes Res"},{"key":"360_CR17","doi-asserted-by":"publisher","first-page":"1338546","DOI":"10.3389\/fphar.2024.1338546","volume":"15","author":"LCG Landeiro","year":"2024","unstructured":"Landeiro LCG, Martins TC, Grigolon RB, Monteiro I, Balardin JB, Padilha E, et al. The burden of systemic therapy administration route in treating HER2-positive breast cancer (for patients, healthcare professionals, and healthcare system): a systematic literature review. Front Pharmacol. 2024;15:1338546.","journal-title":"Front Pharmacol"},{"issue":"1","key":"360_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s41669-022-00361-3","volume":"7","author":"C McCloskey","year":"2023","unstructured":"McCloskey C, Ortega MT, Nair S, Garcia MJ, Manevy F. A systematic review of time and resource use costs of subcutaneous versus intravenous administration of oncology biologics in a hospital setting. Pharmacoecon Open. 2023;7(1):3\u201336.","journal-title":"Pharmacoecon Open"},{"key":"360_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2024.115301","volume":"209","author":"N Mathias","year":"2024","unstructured":"Mathias N, Huille S, Picci M, Mahoney RP, Pettis RJ, Case B, et al. Towards more tolerable subcutaneous administration: review of contributing factors for improving combination product design. Adv Drug Deliv Rev. 2024;209: 115301.","journal-title":"Adv Drug Deliv Rev"},{"issue":"5","key":"360_CR20","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1001\/jamaoncol.2023.0239","volume":"9","author":"M Tang","year":"2023","unstructured":"Tang M, Abdelaal M, Lau J, Ruiz Buenrostro A, Chen M, Zimmermann C, et al. Subcutaneous vs intravenous administration of medications and fluids for patients with cancer in the US and Canada. JAMA Oncol. 2023;9(5):717\u20139.","journal-title":"JAMA Oncol"},{"key":"360_CR21","unstructured":"ARANESP\u00ae (darbepoetin alfa). Prescribing Information. Amgen; 2024. https:\/\/www.pi.amgen.com\/-\/media\/Project\/Amgen\/Repository\/pi-amgen-com\/aranesp\/ckd\/aranesp_pi_hcp_english.pdf. Accessed 6 Dec 2024."},{"key":"360_CR22","unstructured":"DARZALEX FASPRO\u00ae (daratumumab and hyaluronidase-fihj). Prescribing information. Janssen Biotech, Inc.; 2024. https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/DARZALEX+Faspro-pi.pdf. Accessed 6 Dec 2024."},{"key":"360_CR23","unstructured":"HERCEPTIN HYLECTA\u00ae (trastuzumab and hyaluronidase-oysk). Prescribing information. Genentech, Inc.; 2024. https:\/\/www.gene.com\/download\/pdf\/herceptin_hylecta_prescribing.pdf. Accessed 6 Dec 2024."},{"key":"360_CR24","unstructured":"PHESGO\u00ae (pertuzumab trastuzumab and hyaluronidase-zzxf). Prescribing information. Genentech, Inc.; 2024. https:\/\/www.gene.com\/download\/pdf\/phesgo_prescribing.pdf. Accessed 6 Dec 2024."},{"key":"360_CR25","unstructured":"RITUXAN HYCELA\u00ae (rituximab and hyaluronidase human). Prescribing information. Biogen and Genentech USA, Inc.; 2021. https:\/\/www.gene.com\/download\/pdf\/rituxan_hycela_prescribing.pdf. Accessed 6 Dec 2024."},{"key":"360_CR26","unstructured":"VELCADE\u00ae (bortezomib). Prescribing information. Takeda Pharmaceuticals U.S.A., Inc.; 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/021602s046lbl.pdf. Accessed 6 Dec 2024."},{"key":"360_CR27","unstructured":"DARZALEX\u00ae (daratumumab). Prescribing information. Janssen Biotech, Inc.; 2024. https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/DARZALEX-pi.pdf. Accessed 6 Dec 2024."},{"key":"360_CR28","unstructured":"HERCEPTIN\u00ae (trastuzumab). Prescribing Information. Genentech, Inc.; 2024. https:\/\/www.gene.com\/download\/pdf\/herceptin_prescribing.pdf. Accessed 6 Dec 2024."},{"key":"360_CR29","unstructured":"PERJETA\u00ae (pertuzumab). Prescribing information. Genentech, Inc.; 2021. https:\/\/www.gene.com\/download\/pdf\/perjeta_prescribing.pdf. Accessed 6 Dec 2024."},{"key":"360_CR30","unstructured":"RITUXAN\u00ae (rituximab) injection. Prescribing Information. Biogen and Genentech USA, Inc.; 2021. https:\/\/www.gene.com\/download\/pdf\/rituxan_prescribing.pdf. Accessed 6 Dec 2024."},{"issue":"15","key":"360_CR31","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1200\/JCO.21.02810","volume":"40","author":"A Gupta","year":"2022","unstructured":"Gupta A, Eisenhauer EA, Booth CM. The time toxicity of cancer treatment. J Clin Oncol. 2022;40(15):1611\u20135.","journal-title":"J Clin Oncol"},{"issue":"5","key":"360_CR32","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.trecan.2023.01.006","volume":"9","author":"WV Johnson","year":"2023","unstructured":"Johnson WV, Blaes AH, Booth CM, Ganguli I, Gupta A. The unequal burden of time toxicity. Trends Cancer. 2023;9(5):373\u20135.","journal-title":"Trends Cancer"},{"issue":"12","key":"360_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.apjon.2024.100610","volume":"11","author":"C Nwozichi","year":"2024","unstructured":"Nwozichi C, Omolabake S, Ojewale MO, Faremi F, Brotobor D, Olaogun E, et al. Time toxicity in cancer care: a concept analysis using Walker and Avant\u2019s method. Asia Pac J Oncol Nurs. 2024;11(12): 100610.","journal-title":"Asia Pac J Oncol Nurs"},{"key":"360_CR34","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1200\/GO.21.00158","volume":"7","author":"L Cool","year":"2021","unstructured":"Cool L, Missiaen J, Debruyne P, Pottel H, Foulon V, Lefebvre T, et al. Oncologic home-hospitalization delivers a high-quality and patient-centered alternative to standard ambulatory care: results of a randomized-controlled equivalence trial. JCO Glob Oncol. 2021;7:1564\u201371.","journal-title":"JCO Glob Oncol"}],"container-title":["Oncology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-025-00360-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40487-025-00360-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-025-00360-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T11:44:30Z","timestamp":1757245470000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40487-025-00360-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,16]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["360"],"URL":"https:\/\/doi.org\/10.1007\/s40487-025-00360-4","relation":{},"ISSN":["2366-1070","2366-1089"],"issn-type":[{"value":"2366-1070","type":"print"},{"value":"2366-1089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,16]]},"assertion":[{"value":"15 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Robert Epstein is co-founder, CEO, and President of Epstein Health, LLC. JoAnn Krenitsky is co-founder and SVP of Epstein Health, LLC. Phillip Sarocco is an employee and shareholder of Halozyme Therapeutics, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Institutional review board (IRB) approval was obtained prior to patient recruitment; the final survey document and research plan received IRB review exemption by the Sterling IRB. This research was conducted according to the Helsinki Declaration. All HIPAA\/patient privacy requirements were followed for patient recruitment, communication, obtaining and analyzing data, and by the participating personnel\/facilities. All participants provided consent prior to participating in the online survey.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}